Skip to main content
Top
Published in: Infection 4/2018

Open Access 01-08-2018 | Original Paper

Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project

Authors: Justyna D. Kowalska, Magdalena Ankiersztejn-Bartczak, Leah Shepherd, Amanda Mocroft

Published in: Infection | Issue 4/2018

Login to get access

Abstract

Introduction

Early treatment remains the most effective HIV prevention strategy; poor linkage to care after HIV diagnosis may compromise this benefit. We sought to better understand patient characteristics and their association with virological suppression (VS) following cART initiation.

Methods

The TAK project collects pre-linkage to care and clinical data on patients diagnosed with HIV in voluntary testing facilities in central Poland. Data collected for persons diagnosed in 2010–2013 were linked with HIV clinic records. Individuals linked to care who commenced cART were followed from until the earliest of first VS (HIV RNA < 50 copies/ml), last visit, death or 6 January 2016. Cox-proportional hazard models were used to identify factors associated with first viral suppression.

Results

232 persons were HIV positive, 144 (62%, 95% CI 55, 68%) linked to care, 116 (81% of those linked to care, 95% CI 73, 87%) started cART during follow up, of which 113 (97%, 95% CI 93, 99%) achieved VS. Non-PI based regimen (for integrase inhibitors aHR: 5.03: 1.90, 13.32) and HLA B5701-positive (aHR: 3.97: 1.33, 11.85) were associated with higher chance of VS. Unknown syphilis status (aHR: 0.27: 0.13, 0.57) and higher HIV RNA (aHR a tenfold increase: 0.56: 0.42, 0.75) remained associated with lower chance of VS.

Conclusions

Although a low proportion of persons were linked to care, almost all those linked to care started cART and achieved rapid VS. The high rates of VS were irrespective of prior HIV-associated risk behaviours. Linkage to care remains the highest priority in prevention strategies in central Poland.
Literature
1.
go back to reference Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.CrossRefPubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.CrossRefPubMedPubMedCentral
2.
go back to reference Kowalska JD, Wojcik G, Rutkowski J, Ankiersztejn-Bartczak M, Siewaszewicz E. Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations—a message for Central and Eastern Europe. PLoS One. 2017;12:e0186131.CrossRefPubMedPubMedCentral Kowalska JD, Wojcik G, Rutkowski J, Ankiersztejn-Bartczak M, Siewaszewicz E. Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations—a message for Central and Eastern Europe. PLoS One. 2017;12:e0186131.CrossRefPubMedPubMedCentral
4.
go back to reference Parczewski M, Siwak E, Leszczyszyn-Pynka M, Cielniak I, Burkacka E, Pulik P, et al. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. J Int AIDS Soc. 2017;20:21847.CrossRefPubMedPubMedCentral Parczewski M, Siwak E, Leszczyszyn-Pynka M, Cielniak I, Burkacka E, Pulik P, et al. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. J Int AIDS Soc. 2017;20:21847.CrossRefPubMedPubMedCentral
7.
go back to reference Kowalska JD, Oprea C, de Witt S, Pozniak A, Gokengin D, Youle M, et al. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration—a comprehensive meeting report. HIV Med. 2016;18(5):370–5.CrossRefPubMed Kowalska JD, Oprea C, de Witt S, Pozniak A, Gokengin D, Youle M, et al. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration—a comprehensive meeting report. HIV Med. 2016;18(5):370–5.CrossRefPubMed
8.
go back to reference Ankiersztejn-Bartczak M, Firlag-Burkacka E, Czeszko-Paprocka H, Kubicka J, Cybula A, Horban A, et al. Factors responsible for incomplete linkage to care after HIV diagnosis: preliminary results from the Test and Keep in Care (TAK) project. HIV Med. 2015;16:88–94.CrossRefPubMed Ankiersztejn-Bartczak M, Firlag-Burkacka E, Czeszko-Paprocka H, Kubicka J, Cybula A, Horban A, et al. Factors responsible for incomplete linkage to care after HIV diagnosis: preliminary results from the Test and Keep in Care (TAK) project. HIV Med. 2015;16:88–94.CrossRefPubMed
9.
go back to reference Kowalska JD, Shepherd L, Ankiersztejn-Bartczak M, Cybula A, Czeszko-Paprocka H, Firlag-Burkacka E, et al. Poor linkage to care despite significant improvement in access to early cART in Central Poland—data from Test and Keep in Care (TAK) Project. PLoS One. 2016;11:e0162739.CrossRefPubMedPubMedCentral Kowalska JD, Shepherd L, Ankiersztejn-Bartczak M, Cybula A, Czeszko-Paprocka H, Firlag-Burkacka E, et al. Poor linkage to care despite significant improvement in access to early cART in Central Poland—data from Test and Keep in Care (TAK) Project. PLoS One. 2016;11:e0162739.CrossRefPubMedPubMedCentral
10.
go back to reference Shepherd LA-BM., Cybula A, Czeszko-Paprocka H, Firląg-Burkacka E, Horban A, Mocroft A, Kowalska JD. Poor linkage to care despite significant improvement in access to early cART—data from Test and Keep in Care (TAK) project. In: 15th European AIDS conference. Barcelona 21–24 October 2015. Abstr. Nr. PS 8/4. Shepherd LA-BM., Cybula A, Czeszko-Paprocka H, Firląg-Burkacka E, Horban A, Mocroft A, Kowalska JD. Poor linkage to care despite significant improvement in access to early cART—data from Test and Keep in Care (TAK) project. In: 15th European AIDS conference. Barcelona 21–24 October 2015. Abstr. Nr. PS 8/4.
12.
go back to reference Mirandola M, Gios L, Sherriff N, Pachankis J, Toskin I, Ferrer L, et al. Socio-demographic characteristics, sexual and test-seeking behaviours amongst men who have sex with both men and women: results from a bio-behavioural survey in 13 European cities. AIDS Behav. 2017;21(10):3013–25.CrossRefPubMed Mirandola M, Gios L, Sherriff N, Pachankis J, Toskin I, Ferrer L, et al. Socio-demographic characteristics, sexual and test-seeking behaviours amongst men who have sex with both men and women: results from a bio-behavioural survey in 13 European cities. AIDS Behav. 2017;21(10):3013–25.CrossRefPubMed
14.
go back to reference Stahlman S, Hargreaves JR, Sprague L, Stangl AL, Baral SD. Measuring sexual behavior stigma to inform effective HIV prevention and treatment programs for key populations. JMIR Public Health Surveill. 2017;3:e23.PubMedPubMedCentral Stahlman S, Hargreaves JR, Sprague L, Stangl AL, Baral SD. Measuring sexual behavior stigma to inform effective HIV prevention and treatment programs for key populations. JMIR Public Health Surveill. 2017;3:e23.PubMedPubMedCentral
15.
go back to reference Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis. 2011;52:S214–22.CrossRefPubMedPubMedCentral Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis. 2011;52:S214–22.CrossRefPubMedPubMedCentral
17.
go back to reference Rosinska M, Simmons R, Marzec-Boguslawska A, Janiec J, Porter K. Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care. 2016;28:423–31.CrossRefPubMed Rosinska M, Simmons R, Marzec-Boguslawska A, Janiec J, Porter K. Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care. 2016;28:423–31.CrossRefPubMed
18.
go back to reference Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127–36.CrossRefPubMed Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127–36.CrossRefPubMed
19.
go back to reference Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3:e410–20.CrossRefPubMedPubMedCentral Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3:e410–20.CrossRefPubMedPubMedCentral
20.
go back to reference Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191–210.CrossRefPubMedPubMedCentral Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191–210.CrossRefPubMedPubMedCentral
21.
go back to reference Proceedings of the 8th romanian national HIV/AIDS congress and the 3rd Central European HIV forum: Sibiu, Romania. 5–7 May 2016. BMC Infect Dis. 2016;16 Suppl 3:290. Proceedings of the 8th romanian national HIV/AIDS congress and the 3rd Central European HIV forum: Sibiu, Romania. 5–7 May 2016. BMC Infect Dis. 2016;16 Suppl 3:290.
22.
go back to reference Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, et al. Differential Immunodominance Hierarchy of Cd8 + T Cell Responses in Hla-B*27:05 and B*27:02-Mediated Control of Hiv-1 Infection. J Virol. 2017;16(Suppl 3):290. Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, et al. Differential Immunodominance Hierarchy of Cd8 + T Cell Responses in Hla-B*27:05 and B*27:02-Mediated Control of Hiv-1 Infection. J Virol. 2017;16(Suppl 3):290.
23.
go back to reference Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000;97:2709–14.CrossRefPubMed Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000;97:2709–14.CrossRefPubMed
24.
go back to reference Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, et al. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. HIV Med. 2016;17:380–4.CrossRefPubMed Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, et al. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. HIV Med. 2016;17:380–4.CrossRefPubMed
25.
go back to reference Remien RH, Dolezal C, Wagner GJ, Goggin K, Wilson IB, Gross R, et al. The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention. AIDS Behav. 2014;18:1541–7.CrossRefPubMedPubMedCentral Remien RH, Dolezal C, Wagner GJ, Goggin K, Wilson IB, Gross R, et al. The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention. AIDS Behav. 2014;18:1541–7.CrossRefPubMedPubMedCentral
26.
go back to reference Parczewski M, Leszczyszyn-Pynka M, Witak-Jedra M, Maciejewska K, Rymer W, Szymczak A, et al. Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype. J Antimicrob Chemother. 2015;70:233–42.CrossRefPubMed Parczewski M, Leszczyszyn-Pynka M, Witak-Jedra M, Maciejewska K, Rymer W, Szymczak A, et al. Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype. J Antimicrob Chemother. 2015;70:233–42.CrossRefPubMed
27.
go back to reference Stanczak GP, Stanczak JJ, Firlag-Burkacka E, Wiercinska-Drapalo A, Leszczyszyn-Pynkad M, Jablonowska E, et al. Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland. Przegl Epidemiol. 2007;61:29–34.PubMed Stanczak GP, Stanczak JJ, Firlag-Burkacka E, Wiercinska-Drapalo A, Leszczyszyn-Pynkad M, Jablonowska E, et al. Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland. Przegl Epidemiol. 2007;61:29–34.PubMed
28.
go back to reference Phillips AN, Munderi P, Revill PA, El-Sadr WM, Lundgren JD. Antiretroviral therapy recommendations for the global community: aspiration versus reality. AIDS. 2014;28:939–41.CrossRefPubMed Phillips AN, Munderi P, Revill PA, El-Sadr WM, Lundgren JD. Antiretroviral therapy recommendations for the global community: aspiration versus reality. AIDS. 2014;28:939–41.CrossRefPubMed
29.
go back to reference Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, et al. Community perspective on the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med. 2015;16:10–3.CrossRefPubMedPubMedCentral Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, et al. Community perspective on the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med. 2015;16:10–3.CrossRefPubMedPubMedCentral
30.
go back to reference Group ISToATS, Lundgren J, Babiker A, Gordin F, Emery S, Fatkenheuer G, et al. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015;16:1–9. Group ISToATS, Lundgren J, Babiker A, Gordin F, Emery S, Fatkenheuer G, et al. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015;16:1–9.
31.
go back to reference Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8:e55312.CrossRefPubMedPubMedCentral Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8:e55312.CrossRefPubMedPubMedCentral
32.
go back to reference Kowalska JD, Grzeszczuk A, Pyziak-Kowalska K, Marzec-Bogusławska A, Rosińska M, Ankiersztejn-Bartczak M, Horban A. Shaping the HIV epidemic in Poland—proceedings from the first Polish workshop on cascade of care in HIV. HIV AIDS Rev 2017;16:130–3.CrossRef Kowalska JD, Grzeszczuk A, Pyziak-Kowalska K, Marzec-Bogusławska A, Rosińska M, Ankiersztejn-Bartczak M, Horban A. Shaping the HIV epidemic in Poland—proceedings from the first Polish workshop on cascade of care in HIV. HIV AIDS Rev 2017;16:130–3.CrossRef
Metadata
Title
Cascade of care and factors associated with virological suppression among HIV-positive persons linked to care in the Test and Keep in Care (TAK) project
Authors
Justyna D. Kowalska
Magdalena Ankiersztejn-Bartczak
Leah Shepherd
Amanda Mocroft
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1154-0

Other articles of this Issue 4/2018

Infection 4/2018 Go to the issue